Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: Analysis of dexlansoprazole MR clinical trial data

American Journal of Gastroenterology

Volumn 106, Issue 11, 2011, Pages 1953-1960

  Metz, David C ^a   Pilmer, Betsy L ^b   Han, Cong ^b   Perez, M Claudia ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; LANSOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GASTRIN BLOOD LEVEL; HEARTBURN; HUMAN; HYPERGASTRINEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; WOUND HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ESOPHAGITIS; FEMALE; GASTRIC ACID; GASTRINS; HEARTBURN; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WITHHOLDING TREATMENT;

EID: 80655147064     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.220     Document Type: Article

References (23)

1. Kahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal refl ux disease. Gastroenterology 2008; 135: 1383-91, 1391 e1-5.
2. Donnellan C, Sharma N, Preston C et al. Medical treatments for the maintenancetherapy of refl ux oesophagitis and endoscopic negative refl ux disease. Cochrane Database Syst Rev 2004, CD003245.
3. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-8. (Pubitemid 27525091)
4. Cui G, Waldum HL. Physiological and clinical signifi cance of enterochromaffi n-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 2007; 13: 493-6. (Pubitemid 46210913)
5. Waldum HL, Qvigstad G, Fossmark R et al. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2010; 45: 389-94.
6. Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion aft er therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 39-46. (Pubitemid 44902862)
7. FDA. Rebound of gastric acid secretion. 2000: Available at: http://www. fda.gov/ohrms/dockets/ac/00/backgrd/3650b1a-11.pdf. Accessed 21 June 2010.
8. Reimer C, Sondergaard B, Hilsted L et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers aft er withdrawal of therapy. Gastroenterology 2009; 137: 80-7, 87 e1.
9. Niklasson A, Lindstrom L, Simren M et al. Dyspeptic symptom development aft er discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105: 565-71.
10. Aslam N, Wright R. Dexlansoprazole MR. Expert Opin Pharmacother 2009; 10: 2329-36.
11. Metz DC, Vakily M, Dixit T et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcomethe limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 29: 928-37.
12. Vakily M, Zhang W, Wu J et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Releasetechnology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25: 627-38.
13. Davies SL. Dexlansoprazole for thetreatment of esophagitis and GERD. Drugs Today (Barc) 2010; 46: 75-80.
14. Gillen D, Wirz AA, Ardill JE et al. Rebound hypersecretion aft er omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-47. (Pubitemid 29055344)
15. Sharma P, Shaheen NJ, Perez MC et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731-41.
16. Metz DC, Howden CW, Perez MC et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-releasetechnology, eff ectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 742-54.
17. Howden CW, Larsen LM, Perez MC et al. Clinical trial: effi cacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis- maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009; 30: 895-907.
18. Laine L, Ahnen D, McClain C et al. Review article: potential gastrointestinal eff ects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68. (Pubitemid 30352732)
19. Lanzon-Miller S, Pounder RE, Hamilton MR et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment wiTheither ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239-51.
20. Sanduleanu S, Stridsberg M, Jonkers D et al. Serum gastrin and chromogranin A during medium-and long-term acid suppressivetherapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 145-53. (Pubitemid 29090008)
21. Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33: 206-9. (Pubitemid 32762889)
22. Raghunath AS, O ' Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 (Suppl 1): 55-63. (Pubitemid 41153080)
23. Van Soest EM, Siersema PD, Dieleman JP et al. Persistence and adherenceto proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006; 24: 377-85. (Pubitemid 43972906)